SecBot SecBot
S-3 ·Filed Mar 31, 2026

ONCY

ONCOLYTICS BIOTECH INC
BEARISH
Impact 6/10
Horizonweeks Processed7mo ago SEC0001104659-26-038078
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

Monitor for future prospectus supplements that will disclose specific offering terms. The large size relative to market cap suggests this could be a significant dilutive event. Given the company's clinical-stage status and lack of revenue, this capital raise is likely necessary for operations, but represents substantial shareholder dilution risk.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.9300
T+0 close · Mar 31, 2026 · via day close
Latest settled
+3.39%
T+60 · $0.9615
Vs SPY
−9.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $0.9300entry
  2. T+1 · 8mo ago +3.23%α +3.15% · $0.9600
  3. T+5 · 7mo ago +11.83%α +8.06% · $1.04
  4. T+20 · 7mo ago −6.45%α −16.17% · $0.8700
  5. T+60 · 5mo ago +3.39%α −9.99% · $0.9615
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech filed a shelf registration (S-3) to offer up to $250 million in securities, including common stock, preferred stock, warrants, purchase contracts, and units. This filing replaces a prior registration and carries forward $139 million in unsold securities. The shelf allows the company to raise capital opportunistically over time, signaling potential future dilution.

Key Financial Metrics

Offering Size
$250.0M
Dilution
173%

Key Facts

  • Filed S-3 shelf registration for up to $250 million in securities
  • Includes common stock, preferred stock, warrants, purchase contracts, and units
  • Carries forward $139 million in unsold securities from a prior registration
  • Market cap is $91 million, meaning the offering could result in over 170% dilution if fully utilized
  • Recent insider activity shows minimal buying ($15K total)
  • Company recently redomesticated to Nevada from Canada

Financial Impact

Up to $250 million in potential dilution, representing 173% of current market cap

dilutionmarket capshare countequity value

Risk Factors

  • Significant dilution to existing shareholders if the full $250 million is issued
  • Potential for opportunistic timing at low stock prices
  • No guaranteed use of proceeds specified, increasing uncertainty
  • Clinical-stage biotech with no revenue, increasing investment risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001104659-26-038078
Document: tm2610569d1_ex3-3.htm0001104659-26-038078
Document: tm2610569d1_exfilingfees.htm0001104659-26-038078
Document: tm2610569d1_ex5-1.htm0001104659-26-038078
Document: tm2610569d1_ex3-2.htm0001104659-26-038078
Document: tm2610569d1_ex5-2.htm0001104659-26-038078
Document: tm2610569d1_ex23-1.htm0001104659-26-038078
Document: 0001104659-26-038078-index-headers.html0001104659-26-038078
Document: 0001104659-26-038078-index.html0001104659-26-038078
Document: 0001104659-26-038078.txt0001104659-26-038078

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026